These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15281319)

  • 1. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
    Lamm DL
    Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of intravesical therapy for superficial bladder cancer.
    Lamm DL
    Urol Clin North Am; 1992 Aug; 19(3):573-80. PubMed ID: 1636241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM; Morales A; Lamm DL
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical instillations of BCG and bladder carcinoma in situ].
    Haab F; Dauge MC; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):988-94; discussion 992-3. PubMed ID: 8305942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of carcinoma in situ under intravesical Romanian Bacille Calmette-Guérin therapy.
    Geavlete P; Taşcă C
    Rom J Morphol Embryol; 1991; 37(1-2):69-74. PubMed ID: 1801982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
    Lamm DL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-dose BCG in the therapy of superficial neoplasms of the bladder].
    Francesco Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A; Aragona F; Tejerizo JC; Pagano F
    Arch Esp Urol; 1990 Jun; 43(5):503-7. PubMed ID: 2202264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma in situ.
    Lamm DL
    Urol Clin North Am; 1992 Aug; 19(3):499-508. PubMed ID: 1636234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.